iGan Partners Portfolio Update: Momentum Across Medtech and Health Data
Flosonics Medical announced a development contract, valued at up to
Exact Imaging delivered 166% year-over-year revenue growth in its first 12 months following a strategic transition from a single international distribution model to a direct sales and expanded distribution network approach. The company also strengthened its North American direct sales team, and the body of peer-reviewed literature supporting ExactVu now exceeds 140 published papers.
MolecuLight and The Royal Orthopaedic Hospital NHS Foundation Trust announced the publication of the first clinical study evaluating fluorescence imaging during orthopaedic surgery. The prospective 10-patient pilot extends MolecuLight's clinical evidence base beyond chronic wound care into perioperative surgical applications.
Cosm Medical entered a licensing and collaboration agreement with Duke Health and Mayo Clinic to develop and commercialize Gynethotics Recovery, a new class of personalized devices for recovery after pelvic reconstructive surgery, built on Cosm's digital gynecology platform combining medical imaging and 3D printing.
Marble launched a dedicated medical records service for claimants under the Pan-Canadian Claimants' Compensation Plan, the
Segmed provided the data behind a new paper with Stanford University and the University of Washington School of Medicine, published in The International Journal of Cardiovascular Imaging, which tested 54 large language model configurations on cardiac imaging reports and found that open-weight models can approach the agreement of expert radiologists.
View original content to download multimedia:https://www.prnewswire.com/news-releases/igan-partners-portfolio-update-momentum-across-medtech-and-health-data-302875784.html
SOURCE iGan Partners
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- In HelloNation, Funeral Planning Expert George Sullivan III Discusses How to Personalize a Funeral Service
- BUTLER NATIONAL CORPORATION ANNOUNCES FIRST QUARTER 2027 FINANCIAL RESULTS
- Esperovax Announces U.S. Patent Allowance for In Vivo Therapeutic Protein Expression Platform
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share